Competitive Technologies anticipates $1M revenue from sales of Calmare Pain Therapy Treatment

Competitive Technologies, Inc. (NYSE Amex:CTT) today announced it expects revenue from sales of its Calmare® Pain Therapy Treatment for the fourth quarter of fiscal 2010 to be about $1 million, nearly double that of the prior quarter. The Company expects significant additional growth in Calmare medical device sales in upcoming quarters resulting from the growing U.S. sales force of over 35 sales representatives.

"Calmare pain therapy is the only highly effective treatment for chemotherapy-induced peripheral neuropathy (CIPN) without the harmful, adverse side effects of narcotic pain killers," said John B. Nano, CTT's Chairman, President and CEO. "From the growing body of evidence-based patient outcomes we know that in addition to CIPN, our Calmare device successfully treats chronic neuropathic and oncologic pain resulting from cancer, phantom limb syndrome, failed back surgery, sciatica, spinal stenosis, shingles and other maladies. 

Calmare is now available to treat pain patients at Virginia Commonwealth University's Massey Cancer Center, the University of Wisconsin, Madison's Paul Carbone Cancer Center, the University of Miami's Pain Management Center, and the Mayo Clinic in Rochester, Minnesota. Additionally, patients are being treated with Calmare at hospitals and clinics in Massachusetts, New York, Virginia, Florida, Connecticut, Rhode Island, Utah, and Texas, as well as in Europe and Asia.

The non-invasive Calmare device uses the biophysical "Scrambler Therapy" technology, which was developed in Italy by CTT's client, Professor Giuseppe Marineo. CTT's partner, GEOMC Co. Ltd. of Seoul, Korea is manufacturing the Calmare device, which has U.S. FDA clearance and European Union CE Mark clearance for sales. 

Source:

 Competitive Technologies, Inc.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Neuromuscular training reduces chemotherapy-induced neuropathy and improves patient outcomes